Pivotal bioVenture Partners China, a division of China-based conglomerate Nan Fung Group, has reached a final close for its debut fund with US$150 million in capital commitments. The fund will invest broadly in the pharmaceutical, device and health service sectors, with a focus on incubating new life sciences companies in China by in-licensing products and technologies.